A non-transmissible live attenuated SARS-CoV-2 vaccine.

Autor:	Adler JM; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Martin Vidal R; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Voß A; Institut für Tierpathologie, Freie Universität Berlin, 14163 Berlin, Germany., Kunder S; Institut für Tierpathologie, Freie Universität Berlin, 14163 Berlin, Germany., Nascimento M; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Abdelgawad A; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Langner C; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Vladimirova D; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Osterrieder N; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Gruber AD; Institut für Tierpathologie, Freie Universität Berlin, 14163 Berlin, Germany., Kunec D; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany., Trimpert J; Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany. Electronic address: trimpert.jakob@fu-berlin.de.
Jazyk:	angličtina
Zdroj:	Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2023 Aug 02; Vol. 31 (8), pp. 2391-2407. Date of Electronic Publication: 2023 May 26.
DOI:	10.1016/j.ymthe.2023.05.004
Abstrakt:	Live attenuated vaccines (LAVs) administered via the mucosal route may offer better control of the COVID-19 pandemic than non-replicating vaccines injected intramuscularly. Conceptionally, LAVs have several advantages, including presentation of the entire antigenic repertoire of the virus, and the induction of strong mucosal immunity. Thus, immunity induced by LAV could offer superior protection against future surges of COVID-19 cases caused by emerging SARS-CoV-2 variants. However, LAVs carry the risk of unintentional transmission. To address this issue, we investigated whether transmission of a SARS-CoV-2 LAV candidate can be blocked by removing the furin cleavage site (FCS) from the spike protein. The level of protection and immunity induced by the attenuated virus with the intact FCS was virtually identical to the one induced by the attenuated virus lacking the FCS. Most importantly, removal of the FCS completely abolished horizontal transmission of vaccine virus between cohoused hamsters. Furthermore, the vaccine was safe in immunosuppressed animals and showed no tendency to recombine in vitro or in vivo with a SARS-CoV-2 field strain. These results indicate that removal of the FCS from SARS-CoV-2 LAV is a promising strategy to increase vaccine safety and prevent vaccine transmission without compromising vaccine efficacy. Competing Interests: Declaration of interests Related to this work, Freie Universität Berlin has filed a patent application for the use of sCPD9 and sCPD9-ΔFCS as vaccine. In this application, J.T., N.O., and D.K. are named as inventors of sCPD9. Freie Universität Berlin is collaborating with RocketVax AG for further development of sCPD9-ΔFCS as vaccine and receives funding for research. (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu